|
Market Closed -
London S.E.
16:35:16 13/11/2026 GMT
|
5-day change | 1st Jan Change | ||
| 0.5750 GBX | 0.00% |
|
0.00% | +9.52% |
| 11-11 | EARNINGS AND TRADING: Cavendish cuts dividend; Guardian spin-out | AN |
| 11-11 | Thalia Therapeutics Wraps Up In Vitro Study for Lipisiran Cardiovascular Program | MT |
Company Valuation: Thalia Therapeutics Plc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 15.12 | 8.058 | 4.325 | 2.285 | 2.073 | 4.369 |
| Change | - | -46.71% | -46.33% | -47.18% | -9.28% | 110.82% |
| Enterprise Value (EV) 1 | 11.56 | 6.274 | 2.405 | 1.258 | 1.447 | 3.29 |
| Change | - | -45.75% | -61.66% | -47.72% | 15.04% | 127.44% |
| P/E | -8.72x | -5.22x | -3.35x | -1.63x | -1.69x | -3.09x |
| PBR | 4.13x | 3.78x | 2.07x | 2.03x | 3.2x | 4.09x |
| PEG | - | 0.5x | 0.1x | 0.3x | 0x | 0.1x |
| Capitalization / Revenue | - | - | - | 1,169,806,452x | 284,619,061x | 601,524,091x |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| EV / EBIT | -7.39x | -3.4x | -2.02x | -0.94x | -1.18x | -2.82x |
| EV / FCF | -11.3x | -4.55x | -4.42x | -1.64x | -2.14x | -4.83x |
| FCF Yield | -8.89% | -22% | -22.6% | -61.1% | -46.7% | -20.7% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.009573 | -0.008528 | -0.005521 | -0.005225 | -0.00311 | -0.001699 |
| Distribution rate | - | - | - | - | - | - |
| Net sales | - | - | - | 0.001953 | 0.007282 | 0.007264 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -1.564 | -1.843 | -1.193 | -1.335 | -1.221 | -1.165 |
| Net income 1 | -1.305 | -1.544 | -1.029 | -1.269 | -1.059 | -1.205 |
| Net Debt 1 | -3.556 | -1.784 | -1.92 | -1.027 | -0.626 | -1.079 |
| Reference price 2 | 0.083500 | 0.044500 | 0.018500 | 0.008500 | 0.005250 | 0.005250 |
| Nbr of stocks (in thousands) | 181,080 | 181,080 | 233,780 | 268,780 | 394,780 | 832,280 |
| Announcement Date | 25/02/21 | 24/02/22 | 08/03/23 | 23/04/24 | 06/06/25 | 24/06/26 |
1GBP in Million2GBP
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 13.5M | |
| 17.35x | 6.64x | 12.72x | 1.72% | 66.33B | |
| 32.78x | 8.77x | 28.98x | 0.07% | 60.62B | |
| 38.6x | 6.87x | 20.53x | 0.84% | 55.5B | |
| 44.7x | 6.26x | 29.77x | -.--% | 47.58B | |
| 34.6x | 3.29x | 14.2x | -.--% | 43.69B | |
| -20.57x | 54.42x | -22.49x | -.--% | 37.27B | |
| 36.15x | 8.94x | 23.31x | 0.36% | 36.57B | |
| 40.59x | 7.89x | 26.33x | -.--% | 32.22B | |
| -73.93x | 14x | -75.29x | -.--% | 26.58B | |
| Average | 16.70x | 13.01x | 6.45x | 0.33% | 41B | |
| Weighted average by Cap. | 21.70x | 11.75x | 11.42x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- THAT Stock
- Valuation Thalia Therapeutics Plc
Select your edition
All financial news and data tailored to specific country editions
